Market Access News | pharmaphorum

News

Trump win casts pall over future of Affordable Care Act

As the reality of Donald Trump's victory in the US election starts to sink in, there are concerns about the future of the Affordable Care Act, which provides health insurance for more than

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

News

Blueprint's mastocytosis drug Ayvakit cleared for NHS use

NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis (ASM) by the NHS in England and Wales, including firs

News

Trump claims comprehensive victory in US election

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of R

News

Rosacea case showing redness and inflammatory papules and pustules

Journey slips on FDA approval of rosacea therapy

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.

News

NICE backs first ophthalmic bevacizumab for NHS use

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m

Trump win casts pall over future of Affordable Care Act

Autolus bags FDA approval for leukaemia cell therapy

Blueprint's mastocytosis drug Ayvakit cleared for NHS use

Trump claims comprehensive victory in US election

Journey slips on FDA approval of rosacea therapy

NICE backs first ophthalmic bevacizumab for NHS use

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks